Atossa Therapeutics (ATOS) Proxy Filing summary

Executive summary

• Special Meeting scheduled for January 20, 2026, to be held virtually for all stockholders of record as of December 19, 2025.

• Main purpose is to seek approval for a reverse stock split to increase the per share trading price and maintain Nasdaq listing.

• Board unanimously recommends voting FOR both proposals on the agenda.

• Proxy materials are available online, and multiple voting methods are provided, including online, phone, mail, and during the meeting.

Voting matters and shareholder proposals

• Proposal 1: Approve an amendment to effect a reverse stock split at a ratio between 5:1 and 20:1.

• Proposal 2: Approve adjournment of the meeting if more time is needed to solicit proxies.

• Board recommends voting FOR both proposals.

• Stockholder proposals for the 2026 Annual Meeting must be received by November 26, 2025, to be included in the proxy statement.

Board of directors and corporate governance

• Board has discretion to select the reverse split ratio within the approved range based on market and company conditions.

• No officer or director has a substantial interest in the reverse split proposal not shared by all stockholders.

• Security ownership table shows all directors and executive officers as a group own 9.46% of outstanding shares as of November 1, 2025.